Lycera
Ann Arbor · Founded 2006
About Lycera
Lycera is a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. The company's technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.
Company Facts
- Founded: 2006
- Legal name: Lycera Corp.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $85.9M
- Funding stage: M&A
- Last round: Series B (Jun 2015)
- Website: lycera.com
- Phone: 7342333147
Social Profiles
Canonical: https://fsome.com/organization/lycera-8269397 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.